Skip to main content
. 2023 Nov 15;46(1):95–101. doi: 10.1097/FTD.0000000000001144

TABLE 2.

Participant Characteristics, n = 18, Median (IQR) or n (%)

Demographics and Clinical Characteristics
Intermittent infusion (n = 13) Continuous infusion (n = 5)
Male 8 (62) 4 (80)
Age, yr 69 (61–73) 67 (49–74)
BMI, kg/m2 22.4 (19.2–30.7) 31.6 (26.4–42.9)
SCr at randomization (mg/dL) 0.67 (0.54–1.09) 1.21 (0.66–2.16)
CrCl at randomization (mL/min) 83.7 (69.4–105.4) 92 (77.7–222.8)
CRRT 5 (38) 4 (80)
Comorbidities
 Lung cancer 3 (23) 1 (20)
 COPD 2 (15) 2 (40)
 COVID-19 Coinfection 1 (8) 1 (20)
Beta-lactam at randomization
 Cefepime 7 (54) 4 (80)
 Meropenem 2 (15) 0 (0)
 Piperacillin/tazobactam 4 (31) 1 (20)
Respiratory Isolates, n
Pseudomonas aeruginosa 7 5
Klebsiella pneumoniae 0 1
Klebsiella aerogenes 1 1
Enterobacter cloacae 2 0
Proteus mirabilis 1 0
Cronobacter sakazakii 0 1
Concomitant antibiotics for Gram-negative coverage
 Aminoglycoside 1 (7) 0 (0)
 Fluoroquinolone 2 (15) 0 (0)
 Sulfamethoxazole–trimethoprim 0 (0) 1 (20)

BMI, body mass index; SCr, serum creatinine; CrCl, creatinine clearance; CRRT, continuous renal replacement therapy; COPD, chronic obstructive pulmonary disease.